The COMPASSION-15 trial (21) demonstrated that CAD-CHM significantly improves survival in patients with HER2-negative advanced G/GEJ adenocarcinoma, underscoring its clinical potential. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.